Home Meetings Highlights

Highlights

Summaries and high points from meetings about lung cancer and other thoracic neoplasms.

Latest

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

lungcanc

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib

PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to KEYNOTE-042 Analysis

First-Ever IASLC School of Nursing Held at Latin American Lung Cancer...

lungcanc

Highlights From the 2019 IASLC Latin American Conference in Lung Cancer

lungcanc

IASLC’s Inaugural Mesothelioma Meeting Sets Baseline for Strategic Approach to Patient...

lungcanc

2019 IASLC World Conference on Lung Cancer Updates

lungcanc

Lung Cancer Research Highlights from the 2019 ASCO Annual Meeting

lungcanc

IASLC Targeted Therapies of Lung Cancer Meeting Draws Record Abstract Submissions,...

lungcanc

Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

lungcanc

Inaugural LATAM Awards

lungcanc

Highlights from the NCI Post-Treatment Surveillance Workshop

lungcanc

Top Science in Lung Cancer Featured at WCLC 2018

lungcanc

12 3 4 Page 1 of 4

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib